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Abstract
Background: Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has been associated with a significant
risk of thrombotic events in critically ill patients.
Aim: To summarize the findings of a multinational observational cohort of patients with SARS-CoV-2 and cerebrovascular disease.
Methods: Retrospective observational cohort of consecutive adults evaluated in the emergency department and/or
admitted with coronavirus disease 2019 (COVID-19) across 31 hospitals in four countries (1 February 2020–16 June
2020). The primary outcome was the incidence rate of cerebrovascular events, inclusive of acute ischemic stroke,
intracranial hemorrhages (ICH), and cortical vein and/or sinus thrombosis (CVST).
Results: Of the 14,483 patients with laboratory-confirmed SARS-CoV-2, 172 were diagnosed with an acute cerebrovascular event (1.13% of cohort; 1130/100,000 patients, 95%CI 970–1320/100,000), 68/171 (40.5%) were female and
96/172 (55.8%) were between the ages 60 and 79 years. Of these, 156 had acute ischemic stroke (1.08%; 1080/100,000
95%CI 920–1260/100,000), 28 ICH (0.19%; 190/100,000 95%CI 130–280/100,000), and 3 with CVST (0.02%; 20/100,000,
95%CI 4–60/100,000). The in-hospital mortality rate for SARS-CoV-2-associated stroke was 38.1% and for ICH 58.3%.
After adjusting for clustering by site and age, baseline stroke severity, and all predictors of in-hospital mortality found in
univariate regression (p < 0.1: male sex, tobacco use, arrival by emergency medical services, lower platelet and lymphocyte counts, and intracranial occlusion), cryptogenic stroke mechanism (aOR 5.01, 95%CI 1.63–15.44, p < 0.01), older
age (aOR 1.78, 95%CI 1.07–2.94, p ¼ 0.03), and lower lymphocyte count on admission (aOR 0.58, 95%CI 0.34–0.98,
p ¼ 0.04) were the only independent predictors of mortality among patients with stroke and COVID-19.
Conclusions: COVID-19 is associated with a small but significant risk of clinically relevant cerebrovascular events,
particularly ischemic stroke. The mortality rate is high for COVID-19-associated cerebrovascular complications; therefore, aggressive monitoring and early intervention should be pursued to mitigate poor outcomes.
Keywords
All cerebrovascular diseases/stroke, intracranial hemorrhage, cerebral venous thrombosis, COVID-19
Received: 22 July 2020; accepted: 20 August 2020

Introduction
Thrombotic complications of the novel human coronavirus responsible for the systemic acute respiratory syndrome, SARS-CoV-2, have been well described.1,2
Early reports from Wuhan, China, indicated a 2–5%
risk of acute ischemic stroke among hospitalized
patients with the coronavirus disease 2019 (COVID19).3 Other series have reported that patients with
SARS-CoV-2 are at risk of embolic strokes with
severe deﬁcits and a high in-hospital mortality rate.4–6
This risk may be more than seven times greater for
patients with SARS-CoV-2 than patients with inﬂuenza
according to one comparative analysis.7 Although initial estimates indicated a 1 in 20 risk of stroke in
patients with COVID-19, more recent data report a
rate of 1–2% among hospitalized patients.7

Aims
To better illustrate the relationship between SARSCoV-2 and associated cerebrovascular events (CVE),
we established a multinational registry to estimate the
global incidence rate of these neurologic complications
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among consecutively evaluated patients with COVID19. Furthermore, given the high short-term mortality of
hospitalized patients with COVID-19 (5–20%),8,9 we
sought to evaluate the short-term functional outcomes
and survival of patients with COVID-19 and associated
cerebrovascular disease.

Methods
Study design and participants
A retrospective observational registry involving prospectively gathered data from 17 healthcare networks
(31 unique hospitals) across four countries (USA,
Spain, Egypt, and Romania) was queried.
Participating centers were recruited based on aﬃliation
with the Society of Vascular and Interventional
Neurology (SVIN) and contacts among site investigators. All consecutive patients 18 years of age who
were evaluated in each center’s emergency department
(ED) and/or admitted between 1 February 2020 and 16
June 2020 were eligible for inclusion. To be included,
patients must have been diagnosed with SARS-CoV-2
using oropharyngeal polymerase chain reaction (PCR)
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or IgG and/or IgM antibody presence in the sera using
commercial assays. All imaging to conﬁrm the diagnosis of acute ischemic stroke, intracranial hemorrhage,
or cortical vein and/or dural sinus thrombosis (CVST)
was performed and interpreted at the discretion of the
treating physician. This study was approved under a
waiver of informed consent by the local institutional
review board at each participating center, and it is
reported in accordance with the STrengthening the
Reporting of OBservational studies in Epidemiology
statement.

Data collection
Patient demographic information, including age, sex,
race, and ethnicity, as well as pertinent medical history,
National Institutes of Health Stroke Scale (NIHSS)
score, neuroimaging, treatment, laboratory testing
(hematologic parameters, d-dimer), functional outcome
at the time of discharge using the modiﬁed Rankin
Scale (mRS),10,11 and discharge disposition were captured. De-identiﬁed data elements (including age, which
was binned by decade for de-identiﬁcation purposes)
were documented by local investigators on a HIPAAcompliant, online platform, as previously described,12
and were made accessible to the data coordinating
center (Cooper University Hospital) for analysis.
Intracranial occlusion was deﬁned broadly as any intracranial arterial occlusion identiﬁed on vascular imaging. Stroke etiology was classiﬁed according to the
Trial of Org 10172 in Acute Stroke Treatment as previously described.13 Sites also reported their overall inhospital mortality rate among all COVID-19 patients
throughout the study period. Data elements with a
<50% completion rate (e.g. intubation and/or tracheostomy, length of hospital stay) were not reported in
order to limit the selection bias. Ninety-day outcomes
(including mRS, living situation, and survival) were
unavailable given the recency of the study period and
the generally protracted hospitalizations for COVID-19
patients.

Statistical analysis
No sample-size calculations were performed prior to
data collection. Descriptive statistics were used to summarize continuous and categorical variables. Normality
of continuous data was assessed histographically and
conﬁrmed using the Shapiro–Wilk test. Continuous
variables were reported as medians with interquartile
range. The primary outcome was the incidence rate of
CVEs, which was summated by healthcare institutions
and across the entire cohort, with approximate binomial 95% conﬁdence intervals (95%CI) per 100,000
hospitalized COVID-19 patients using the Agresti–
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Coull method.14 After event rates were found to vary
according to site COVID-19 volume, Pearson’s correlation coeﬃcient was calculated to estimate the association between the COVID-19 volume at individual sites
and (1) CVE incidence rate, (2) stroke incidence rate,
and (3) in-hospital mortality.
As part of the secondary objective, we evaluated the
clinical, laboratory, and radiographic factors that were
associated with in-hospital mortality. In addition to
using the aforementioned descriptive statistics, the
two-sample test of proportions was used to determine
signiﬁcant diﬀerences in-hospital mortality between
each of the various stroke mechanisms. All relevant
covariates were entered into univariate regression
models estimating the odds of mortality among patients
with ischemic stroke. Variables signiﬁcant to p < 0.1 in
these models were added to age and baseline NIHSS
(known signiﬁcant predictors of mortality)15,16 in a
multivariable logistic regression model, which was clustered by site. A separate multivariable model was generated among patients with ischemic stroke due to an
intracranial occlusion estimating the odds of in-hospital
mortality, incorporating age, baseline NIHSS, and all
variables signiﬁcant to p < 0.1 in univariate regression.
All tests were performed at the two-sided level using
STATA 15.0 (College Station, TX), with p  0.05 considered statistically signiﬁcant. As this was an exploratory analysis, p-values are reported for convention and
should be interpreted with caution. No adjustments
were made for multiple comparisons. Missing data
were not imputed. Fully de-identiﬁed data will be
made available upon reasonable request of the corresponding author.

Results
Of the 14,483 patients with laboratory-conﬁrmed
SARS-CoV-2, 172 were diagnosed with an acute CVE
(1.13% of COVID-19 cohort; 1130 per 100,000
patients, 95%CI 970–1320 per 100,000). Among
patients with CVE, 68/171 (40.5%) were female, 94/
138 (68.1%) with reported race were White, and 96/
172 (55.8%) were between the ages 60 and 79 years.
Between sites, CVE rates ranged from 0.19 to 5.04%
(Figure 1), with sites treating more COVID-19 patients
reporting a lower rate of CVE (r ¼0.659, p ¼ 0.004)
and acute ischemic stroke (r ¼ 0.668, p ¼ 0.003). The
most common CVE was acute ischemic stroke,
observed in 156 patients (1.08%; 1080 per 100,000,
95%CI 920–1260 per 100,000), with 28 patients
having radiographically conﬁrmed primary ICH
(0.19%; 190 per 100,000, 95%CI 130–280 per 100,00)
and 3 with CVST (0.02%; 20 per 100,000, 95%CI 4–60
per 100,000). Fourteen patients had acute stroke and
intracerebral hemorrhage (8.1% of cohort), with a
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similar distribution of age and comorbidities as the
overall stroke population in this cohort (Table 1).
Demographic data are summarized in Table 1.
Deﬁcits were generally moderate or severe among

Figure 1. Prevalence of CVEs by site.

Incidence rate of any CVEs and stroke are plotted using vertical bars
(primary y-axis) while the total COVID-19 ED and/or hospitalization rate are
plotted as dots (secondary y-axis).
CVE: cerebrovascular event; COVID-19: coronavirus disease 2019.

patients with stroke (median NIHSS 13 (IQR 5–21))
or ICH (median NIHSS 22 (IQR 7–25)). The most
common mechanism of acute stroke among COVID19 patients was cryptogenic (42.6%) followed by cardioembolism (27.1%). An intracranial occlusion was
identiﬁed in 53/107 patients with intracranial arterial
imaging (49.5%; Table 2).
The median in-hospital COVID-19 mortality rate
was 11.7% (IQR 8.6–18.4%), with no correlation
between COVID-19 volume and in-hospital mortality
among COVID-19 patients (r ¼ 0.002), or among
patients with COVID-19 and CVE (r ¼ 0.01;
Supplemental Figure 1). There was a non-signiﬁcant
variation in mortality across sites (p ¼ 0.09), but this
did not vary signiﬁcantly by site COVID-19 volume
(Supplemental Figures 1 and 2). More than one-third
of patients with acute stroke and COVID-19 died
during hospitalization, while more than half of patients
with ICH and COVID-19 died (Supplemental Table 1).
The median time from stroke onset to death was four
days (IQR 1–10) among patients with stroke, 33 of
whom died within seven days (21.2% of all stroke
patients). The median time from ICH onset to death
was 3.5 days (IQR 1–7), 11 of whom died within seven
days (39.3% of all ICH patients). Although there was

Figure 2. In-hospital mortality rate according to stroke etiology.

The distribution of stroke etiologies is plotted using vertical bars (primary y-axis), and mortality rate according to stroke mechanism is plotted as squares with
standard error bars (secondary y-axis).
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Table 1. Demographic data
All patients with
suspected or
radiographically
confirmed
CVEa (n ¼ 172)

<30

Acute ischemic
stroke (n ¼ 156)

Intracranial
hemorrhage
(n ¼ 28)

Stroke þ
intracranial
hemorrhage
(n ¼ 14)

0/172 (0%)

0/156 (0%)

0/28 (0%)

0/14 (0%)

30–39

5/172 (2.9%)

4/156 (2.6%)

1/28 (3.6%)

0/14 (0%)

40–49

19/172 (11.1%)

15/156 (9.6%)

6/28 (21.4%)

3/14 (21.4%)

50–59

24/172 (14.0%)

20/156 (12.8%)

4/28 (14.3%)

0/14 (0%)

60–69

50/172 (29.1%)

49/156 (31.4%)

4/28 (14.3%)

4/14 (28.6%)

70–79

46/172 (26.7%)

45/156 (28.9%)

5/28 (17.8%)

4/14 (28.6%)

80–89

23/172 (13.4%)

18/156 (11.5%)

8/28 (28.9%)

3/14 (21.4%)

5/172 (2.9%)

5/156 (3.2%)

0/28 (0%)

0/14 (0%)

68/171 (40.5%)

61/155 (39.4%)

10/28 (35.7%)

4/14 (28.6%)

White

94/138 (68.1%)

84/125 (67.2%)

20/24 (83.3%)

10/12 (83.3%)

Black

37/138 (26.8%)

30/125 (28.0%)

3/24 (12.5%)

2/12 (16.7%)

Asian

3/138 (2.2%)

2/125 (1.6%)

1/24 (4.2%)

0/12 (0%)

More than one race

2/138 (1.5%)

2/125 (1.6%)

0/24 (0%)

0/12 (0%)

Other

2/138 (1.5%)

2/125 (1.6%)

0/24 (0%)

0/12 (0%)

62/154 (40.3%)

58/140 (41.4%)

10/27 (37.0%)

6/14 (42.9%)

Emergency medical services

67/115 (58.3%)

59/105 (56.2%)

12/19 (63.2%)

5/10 (50.0%)

Transfer from outside hospital

30/115 (26.1%)

28/105 (26.7%)

6/19 (31.6%)

4/10 (40.0%)

Walk-in/private vehicle

13/115 (11.3%)

13/105 (12.4%)

1/19 (5.3%)

1/10 (10.0%)

5/113 (4.4%)

5/105 (4.8%)

0/19 (0%)

0/10 (0%)

169/172 (98.3%)

153/156 (98.1%)

26/28 (92.9%)

12/14 (85.7%)

12/172 (1.7%)

11/156 (7.1%)

2/28 (7.1%)

2/14 (14.3%)

22/172 (12.8%)

19/156 (12.2%)

3/28 (10.7%)

0/14 (0%)

121/170 (71.2%)

111/154 (72.1%)

18/28 (64.3%)

Age, no. (%)

>89
Sex, no. female (%)
Race, no. (%)

Hispanic ethnicity, no. (%)
Method of arrival, no. (%)

Other
Diagnosis of COVID-19,b no. (%)
Oropharyngeal PCR
Serum IgM and/or IgG
Known COVID-19
exposure, no. (%)
Medical history, no. (%)
Hypertension

9/14 (64.3%)
(continued)
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Table 1. Continued
All patients with
suspected or
radiographically
confirmed
CVEa (n ¼ 172)

Acute ischemic
stroke (n ¼ 156)

Diabetes mellitus

68/168 (40.5%)

65/152 (42.8%)

7/28 (25.0%)

5/14 (35.7%)

Dyslipidemia

61/155 (39.4%)

58/142 (40.1%)

9/25 (36.0%)

6/13 (46.2%)

Atrial fibrillation

30/163 (18.4%)

27/148 (18.2%)

5/22 (18.5%)

2/14 (14.3%)

Congestive heart failure

30/170 (17.7%)

27/154 (17.5%)

6/22 (21.4%)

4/10 (40.0%)

Active tobacco use

17/150 (10.8%)

15/145 (10.3%)

3/26 (11.5%)

1/14 (7.1%)

Prior stroke

19/154 (12.3%)

15/140 (10.7%)

6/27 (22.2%)

2/14 (14.3%)

Chronic renal insufficiency
(stage III/IV or
dialysis-dependent)

18/160 (11.3%)

16/144 (11.1%)

5/28 (17.9%)

3/14 (21.4%)

Chronic obstructive pulmonary
disease and/or asthma

12/148 (8.1%)

11/135 (8.2%)

2/26 (7.7%)

1/14 (7.1%)

9/147 (6.1%)

8/134 (6.0%)

4/26 (15.4%)

3/14 (21.4%)

Cancer

Intracranial
hemorrhage
(n ¼ 28)

Stroke þ
intracranial
hemorrhage
(n ¼ 14)

a

CVE includes acute ischemic stroke, intracranial hemorrhage, or cortical vein and/or dural sinus thrombosis.
9 patients with a CVE, including 8 patients with an acute stroke were diagnosed with COVID-19 using both serum antibodies and oropharyngeal PCR.
CVE: cerebrovascular event; COVID-19: coronavirus disease 2019; PCR: polymerase chain reaction.
b

no signiﬁcant diﬀerence in mortality according to
stroke mechanism (p ¼ 0.22), there was a signiﬁcantly
higher mortality rate among patients with stroke plus
intracranial hemorrhage (OR 4.07, 95%CI 1.19–13.85,
p ¼ 0.03) and a non-signiﬁcantly higher mortality for
stroke of cryptogenic mechanism versus stroke due to
‘‘other’’ mechanisms (p ¼ 0.07), and cryptogenic
strokes versus strokes due to cardioembolism
(p ¼ 0.098; Figure 2). Among all patients with a
stroke, those more likely to die were male (OR 2.16,
95%CI 1.04–4.48, p ¼ 0.04), had more severe deﬁcits
(b ¼ 0.017, 95%CI 0.009–0.026, p < 0.001), and a
cryptogenic stroke mechanism (OR 2.08, 95%CI
0.94–4.63, p ¼ 0.07). When added to age (p ¼ 0.03 in
unadjusted regression) in the ﬁnal multivariable
model after adjustment for all variables signiﬁcant to
p < 0.1 in univariate regression (male sex, tobacco use,
arrival by emergency medical services, lower admission
platelet and lymphocyte counts, and intracranial occlusion)—and after clustering by site—cryptogenic stroke
mechanism (aOR 5.01, 95%CI 1.63–15.44, p < 0.01),
older age (aOR 1.78, 95%CI 1.07–2.94, p ¼ 0.03), and
lower lymphocyte count on admission (aOR 0.58,
95%CI 0.34–0.98 p ¼ 0.04) remained the only independent
predictors
of
in-hospital
mortality
(Supplemental Table 2). Cryptogenic stroke also
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remained the only independent predictor of in-hospital
mortality among patients with an intracranial occlusion
(aOR 5.03, 95%CI 1.99–12.74, p < 0.01; Supplemental
Table 3).

Discussion
In this observational cohort of more than 14,000
COVID-19 patients treated at 31 hospitals in four
countries, approximately 1 in 100 patients were diagnosed with a clinically relevant or radiographically conﬁrmed cerebral infarction. The reported incidence rate
of any CVE varied between 0.19 and over 5% in this
cohort, with a more than twofold higher rate of cryptogenic ischemic stroke (42%) when compared to historic
cohorts (17%)17 and half of patients having an
embolic occlusion. The high prevalence of cryptogenic
infarctions with an embolic radiographic appearance
validates prior reports suggesting a prothrombotic
mechanism of stroke among patients with COVID19.7 Furthermore, the severity of disease in patients
with a cryptogenic (SARS-CoV-2-associated) stroke is
reﬂected by the high mortality rate among cryptogenic
stroke patients with COVID-19 (39%). Importantly,
the early mortality risk resonates with other reports
of increased mortality with SARS-CoV-2 among
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Table 2. Clinical and radiographic features
Acute ischemic stroke (n ¼ 156)

Intracranial hemorrhage (n ¼ 28)

NIHSS at baseline, median (IQR)

13 (5–21) (n ¼ 130)

22 (7–25) (n ¼ 16)

Glasgow Coma Scale at baseline, median (IQR)

n/a

6 (4–15) (n ¼ 15)

Head CT performed, no. (%)

135/151 (89.4%)

28 (100%)

First CT indicating acute stroke, no. (%)

76/132 (57.6%)

n/a

Intracranial hemorrhage on CT, no. (%)

14/132 (10.6%)

28 (100%)

105/156 (67.3%)

14/28 (50.0%)

53/107 (49.5%)

n/a

55/151 (36.4%)

8/27 (29.6%)

45/55 (81.8%)

5/8 (62.5%)

Any vascular imaging performed, no. (%)
Intracranial occlusion identified, no. (%)
MRI brain performed, no. (%)
MRI evidence of acute stroke, no. (%)
CT or MRI location of infarction, no. (%)

n/a

Cortical

81/101 (80.2%)

n/a

Subcortical supratentorial

54/101 (53.5%)

n/a

Infratentorial

12/101 (11.9%)

n/a

Cardioembolism

35/129 (27.1%)

n/a

Large vessel atherosclerotic disease

15/129 (11.6%)

n/a

Small vessel disease

4/129 (3.1%)

n/a

Cryptogenic

55/129 (42.6%)

n/a

Other

11/129 (8.5%)

n/a

Intraparenchymal

n/a

20 (71.4%)

Subarachnoid

n/a

7 (25.0%)

Subdural

n/a

2 (7.1%)

Intraventricular

n/a

8 (28.6%)

Epidural

n/a

0 (0%)

Supratentorial

n/a

13/18 (72.2%)

Infratentorial

n/a

7/18 (38.9%)

IPH volume, median cc (IQR)

n/a

20 (10–66.2) (n ¼ 11)

ICH score, median (IQR)

n/a

3 (1–3) (n ¼ 10)

Stroke etiology, no. (%)

ICH compartment,a no. (%)

IPH location*, no. (%)

(continued)
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Table 2. Continued
Acute ischemic stroke (n ¼ 156)

Intracranial hemorrhage (n ¼ 28)

Coagulopathy

n/a

8/16 (50.0%)

Hypertension

n/a

5/16 (31.3%)

Other

n/a

3/16 (18.8%)

IPH etiology, no. (%)

a

Some patients experienced intracranial hemorrhage in multiple compartments with intraparenchymal involvement of supra- and infratentorial regions.
NIHSS: National Institutes of Health Stroke Scale; IQR: interquartile range; CT: computed tomography; MRI: magnetic resonance imaging; ICH:
intracranial hemorrhage; IPH: intraparenchymal hemorrhage.

patients with comorbid cerebrovascular disease,18
although it vastly exceeds what has been historically
described in non-SARS-CoV2 patients (6% at one
year for patients with cryptogenic stroke vs. 21% for
cardioembolism and large vessel disease).19 This suggests that COVID-19-associated cryptogenic stroke is
a truly unique stroke mechanism with a high probability of early mortality. Whether stroke is a driving factor
for early mortality in COVID-19, or a clinical biomarker of disease severity, should be explored in
future studies.
An unrelated observation was that the hospital
COVID-19 volume was strongly and inversely correlated with the reported CVE rates. Several explanations
may account for this. First, sites with higher volumes of
COVID-19 patients may have broader testing or admission criteria for asymptomatic or mild patients, among
whom a cerebrovascular complication may be less
common. Second, sites with higher volumes of
COVID-19 patients may have experienced signiﬁcant
resource limitations and as such, may have missed
stroke diagnoses among critically ill hospitalized
patients with COVID-19. Third, sites responsible for
rapid triage and management of a large number of
COVID-19 patients may have sought to limit healthcare provider exposure to patients or restrict certain
diagnostic testing (e.g. neuroimaging with CT and/or
MRI) to prevent delays in the care of other patients
while these resources could be decontaminated. And
ﬁnally, sites with higher COVID-19 volumes may
have implemented more aggressive antithrombotic
treatment earlier in the course of hospitalization for
COVID-19. However, data regarding prophylactic
treatment was not captured in this investigation.
Our study also validates recent data from a New
York health system that reported COVID-19 patients
with acute stroke had a higher probability of cryptogenic embolic stroke mechanism with more severe deficits.8 Most patients in our cohort had moderate or
severe deﬁcits according to the NIHSS, with an 80%
prevalence of cortical involvement on neuroimaging
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and 50% rate of intracranial occlusion—consistent
with an embolic mechanism. It is worth noting that
while strokes in this cohort were more severe than in
historic cohorts, we did not account for critical illness
and/or sedation, which could have artiﬁcially augmented the NIHSS in these patients. Regardless of confounding by sedation or critical illness, the observation
that COVID-19 patients with cryptogenic strokes (presumably related to the prothrombotic milieu triggered
by SARS-CoV-2) were signiﬁcantly more likely to die
during their hospitalization speaks to the gravity of
cerebrovascular complications. More importantly, it
should galvanize our eﬀorts to closely monitor for
such complications and manage aggressively when an
event is suspected.

Limitations
While this study is the largest observational cohort of
consecutive COVID-19 patients with cerebrovascular
complications to date, it is limited by its retrospective
nature, inclusion of patients largely representing the
United States and Spain, and unavailability of some
outcome data (e.g. length of stay, 90-day functional
status). Because we prioritized data collection for hospitalized patients with COVID-19 and CVE, we are
unable to report any comparisons between patients
with CVE and those without CVE. The incidence of
CVE observed in this cohort is not reﬂective of the
overall incidence of CVE among COVID-19 patients
because these data were limited to sick patients who
presented to the ED and/or were hospitalized. In addition, sites participating in this study were aﬃliated with
the SVIN, with large referral networks, which could
have confounded the severity of cases and prevalence
of intracranial occlusion. However, among patients
who arrived via transfer from outside institutions,
there was no higher prevalence of an occlusion (6/36
vs. 10/35, p ¼ 0.23) or greater severity of deﬁcits
(median NIHSS 17 vs. 11, p ¼ 0.47) when compared
to patients who arrived by other means (data not
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otherwise shown). In a separately reported analysis
involving 11 of the sites included here, the rate of intracranial occlusion among all-comers with stroke
admitted during a similar study period was 19.6%
(183/933 patients, unpublished data), which is slightly
lower than what has been reported in observational
studies (30%).20 Therefore, we do not believe that
this COVID-19 population reﬂects institutional biases
which could lead to a higher rate of LVO patients, irrespective of COVID-19 status. While we observed a high
rate of cryptogenic stroke in this COVID-19 population, the diagnosis of a cryptogenic mechanism (and
minimum diagnostic testing for stroke evaluation—including long-term cardiac event monitoring,
intracranial vascular imaging, etc.) was left to the discretion of the treating physician. It is possible that
patients with cryptogenic stroke had less comprehensive diagnostic evaluations due to severity of their illness and low probability of survival, which could have
confounded these results. However, the time from
stroke onset to death was a median of four days, indicating that a timely evaluation could have been pursued
to rule out traditional mechanisms of stroke. Stroke
mechanisms in this COVID-19 population are being
reported separately. Furthermore, these data reﬂect
the experience of healthcare centers within and associated with the SVIN network, with 62% of patients
being treated outside the United States. Importantly,
the primary objective of this study was to estimate the
incidence rate of CVE and outcomes at healthcare institutions that could monitor for neurologic complications of COVID-19. More than 80% of patients with
acute ischemic stroke and 100% of patients with ICH
and CVST had radiographically conﬁrmed events. It is
possible, if not probable, that the lack of serial neuroimaging of critically ill patients with COVID-19 may
underestimate the event rates reported in this multicenter study. The question of how best to prevent thrombotic complications in patients with COVID-19 also
remains unanswered. The non-randomized allocation
of treatment in the form of antiplatelet therapy (single
or dual), anticoagulation, or both, in conjunction with
the small number of total stroke patients, precludes a
meaningful comparison of treatment eﬀects. The best
course of treatment can only be clariﬁed by randomized
clinical trials evaluating immunotherapies and antithrombotics or by pooling of these data with other observational studies.

Conclusions
The arterial thrombotic complications of COVID-19
are not to be understated. While the risk of a clinically
relevant stroke was low in this multicenter study, there
was considerable variability in the incidence rate (as
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high as 5%), and the risk of poor outcomes was signiﬁcant. This builds on existing literature suggesting the
stroke risk to be 1%;7,8 however, the risk may be
higher in some populations or those with more frequent
neuroimaging and/or aggressive neurologic monitoring.
It is likely that this approximately 1% risk of clinically
signiﬁcant stroke reﬂects a ﬂoor rate, and the true rate
could be even higher. In our cohort of geographically
distinct and medically unique patients, the observed
high mortality rate validates one recent meta-analysis
of 4448 patients with COVID-1921 using a larger multicenter data set. Patients with stroke may have suﬀered
from a more virulent strain of SARS-CoV-222 and/or
greater complications of COVID-19, which puts them
at a higher risk of long-term disability and in-hospital
mortality. The severity of cerebrovascular disease
during the COVID-19 pandemic may be compounded
by the lack of in-hospital family support with visitor
restrictions, patients being managed in a COVID-19
unit rather than a dedicated stroke unit, and possibly
less contact with physical therapy and occupational
services until patients are liberated from COVID-19
precautions. However, it may also be that the thrombotic complications of the virus could drive the
adverse outcomes. Additional studies are called upon
to ﬁrmly establish COVID-19 as a unique mechanism
of stroke and to better characterize the long-term complications of COVID-19-associated cerebrovascular
disease.
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